This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rodeheffer, R. J. Search for Related Content PubMed PubMed Citation Articles by Rodeheffer, R. J.

VIEWPOINT

Measuring plasma B-type natriuretic peptide in heart failure

Good to go in 2004?

Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MinnesotaUSA

Manuscript received July 22, 2003; revised manuscript received February 23, 2004, accepted March 2, 2004.

^* Reprint requests and correspondence: Dr. Richard J. Rodeheffer, Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street, SW, Rochester, Minnesota 55905 (Email: rodeheffer.richard{at}mayo.edu).

Elevated plasma brain natriuretic (BNP) concentrations correlate with increased cardiac filling pressures. Therefore, increased BNP has been proposed as a marker for asymptomatic ventricular dysfunction, as an aid in the diagnosis of cardiac dyspnea, as an end point to assess the efficacy of heart failure therapy, and as a prognostic marker in heart failure. An understanding of the utility of BNP requires an appreciation of the sensitivity, specificity, and diagnostic accuracy of BNP in each of these clinical situations. At this time, there is strong evidence for the value of BNP in the evaluation of dyspnea of uncertain cause. Further population studies will need to be performed to refine the application of BNP to community cohorts and to determine its clinical value and cost-effectiveness as a screening tool in the early diagnosis of ventricular dysfunction. To make optimal use of BNP for the assessment of heart failure therapy and prognosis in individual patients, physicians will require additional information on the biological variability of BNP. Studies comparing the sensitivity, specificity, and predictive value of the available BNP and N-terminal pro-BNP assays need to be conducted in each of these clinical settings.

Abbreviations and Acronyms   ANP = atrial natriuretic peptide   AUC = area under the receiver operating curve   BNP = B-type natriuretic peptide   CHF = congestive heart failure   EF = ejection fraction   LV = left ventricular   LVD = left ventricular dysfunction   NT-proBNP = N-terminal pro-B-type natriuretic peptide

This article has been cited by other articles:

				R. Pizarro, O. O. Bazzino, P. F. Oberti, M. Falconi, F. Achilli, A. Arias, J. G. Krauss, and A. M. Cagide Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation. J. Am. Coll. Cardiol., September 15, 2009; 54(12): 1099 - 1106. [Abstract] [Full Text] [PDF]

				K. Fatema, K. R. Bailey, G. W. Petty, I. Meissner, M. Osranek, A. A. Alsaileek, B. K. Khandheria, T. S. Tsang, and J. B. Seward Increased Left Atrial Volume Index: Potent Biomarker for First-Ever Ischemic Stroke Mayo Clin. Proc., October 1, 2008; 83(10): 1107 - 1114. [Abstract] [Full Text] [PDF]

				B. H. Cuthbertson, A. R. Amiri, B. L. Croal, S. Rajagopalan, O. Alozairi, J. Brittenden, and G. S. Hillis Utility of B-type natriuretic peptide in predicting perioperative cardiac events in patients undergoing major non-cardiac surgery Br. J. Anaesth., August 1, 2007; 99(2): 170 - 176. [Abstract] [Full Text] [PDF]

				F. H. Rutten, M.-J. M. Cramer, N. P.A. Zuithoff, J.-W. J. Lammers, W. Verweij, D. E. Grobbee, and A. W. Hoes Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease Eur J Heart Fail, June 1, 2007; 9(6-7): 651 - 659. [Abstract] [Full Text] [PDF]

				K. A. Ammar, S. J. Jacobsen, D. W. Mahoney, J. A. Kors, M. M. Redfield, J. C. Burnett Jr, and R. J. Rodeheffer Prevalence and Prognostic Significance of Heart Failure Stages: Application of the American College of Cardiology/American Heart Association Heart Failure Staging Criteria in the Community Circulation, March 27, 2007; 115(12): 1563 - 1570. [Abstract] [Full Text] [PDF]

				F. Liang, J. O'Rear, U. Schellenberger, L. Tai, M. Lasecki, G. F. Schreiner, F. S. Apple, A. S. Maisel, N. S. Pollitt, and A. A. Protter Evidence for Functional Heterogeneity of Circulating B-Type Natriuretic Peptide J. Am. Coll. Cardiol., March 13, 2007; 49(10): 1071 - 1078. [Abstract] [Full Text] [PDF]

				J. P. Goetze, R. Mogelvang, L. Maage, H. Scharling, P. Schnohr, P. Sogaard, J. F. Rehfeld, and J. S. Jensen Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction Eur. Heart J., December 2, 2006; 27(24): 3004 - 3010. [Abstract] [Full Text] [PDF]

				S G Ray Natriuretic peptides in heart valve disease Heart, September 1, 2006; 92(9): 1194 - 1197. [Abstract] [Full Text] [PDF]

				M. D. Ginsberg, M. D. Hill, Y. Y. Palesch, K. J. Ryckborst, and D. Tamariz The ALIAS Pilot Trial: A Dose-Escalation and Safety Study of Albumin Therapy for Acute Ischemic Stroke--I: Physiological Responses and Safety Results Stroke, August 1, 2006; 37(8): 2100 - 2106. [Abstract] [Full Text] [PDF]

				M. Hlatky and P. Heidenreich The Value of BNP Testing. Arch Intern Med, May 22, 2006; 166(10): 1063 - 1064. [Full Text] [PDF]

				R. E. Gilbert, K. Connelly, D. J. Kelly, C. A. Pollock, and H. Krum Heart Failure and Nephropathy: Catastrophic and Interrelated Complications of Diabetes Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 193 - 208. [Abstract] [Full Text] [PDF]

				A. Nohria and M. M. Givertz B-Type Natriuretic Peptide and the Stressed Heart J. Am. Coll. Cardiol., February 21, 2006; 47(4): 749 - 751. [Full Text] [PDF]

				S. P. Salzberg, F. Filsoufi, A. Anyanwu, K. von Harbou, A. Gass, S. P. Pinney, A. Carpentier, and D. H. Adams High-Risk Mitral Valve Surgery: Perioperative Hemodynamic Optimization with Nesiritide (BNP) Ann. Thorac. Surg., August 1, 2005; 80(2): 502 - 506. [Abstract] [Full Text] [PDF]

				D. Crook and H. Smith Brain natriuretic peptide in heart failure: an improving prognosis? Eur. Heart J., June 1, 2005; 26(11): 1052 - 1053. [Full Text] [PDF]

				D. Detaint, D. Messika-Zeitoun, J.-F. Avierinos, C. Scott, H. Chen, J. C. Burnett Jr, and M. Enriquez-Sarano B-Type Natriuretic Peptide in Organic Mitral Regurgitation: Determinants and Impact on Outcome Circulation, May 10, 2005; 111(18): 2391 - 2397. [Abstract] [Full Text] [PDF]